Abstract: A composition for use in medicine or as a dietary supplement, the composition including at least one complex or salt of trivalent metal cation (Me3+) with inorganic polyphosphate (polyP), wherein the trivalent metal cation (Me3+) is selected from the elements of the group consisting of Al, In, La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb and Lu.

Abstract: The invention relates to the application of inorganic polyphosphates (polyP) and complexes of polyP and calcium [polyP (Ca2+ complex)] for prophylaxis and treatment of osteoporosis and other bone diseases by inducing hydroxyapatite formation and decreasing osteoclastogenesis. PolyP and polyP (Ca2+ complex) can be used both as a drug or food supplement and as a material to be injected into bone tissue.

Abstract: Anti-infective and biofilm-inhibiting activities of aryl isoquinoline-derivatives of the general formulae 1 to 3 are described.

Abstract: The present invention concerns a process for preparing products having layers/films of silicon derivates comprising the following steps: a) Preparing a mould made of elastomeric material and having a plurality of grooves with mutual spacing in the range from 1 ?m to 1 mm; b) incubating the mould of step a) in a solution of silicateins in a range of temperatures from 2 to 10° C. and in a range of time from a few minutes to 103 hours; c) providing a target substrate of silicon or oxides thereof; d) transferring the silicateins from the mould to the said target substrate through soft lithography technique for a time period from a few seconds to 103 hours and removing the elastomeric mould; e) incubating the substrate with patterned silicateins of step d) in a solution of one or more precursors belonging to the class of silane compounds for a time period in a range from a few seconds to 103 hours in a temperature range from 2° C. to 25° C.

Abstract: Anti-infective and biofilm-inhibiting activities of aryl isoquinoline-derivatives of the general formulae 1 to 3 are described.

Abstract: The invention concerns the application of silintaphin-1 in the sustainable fabrication of hierarchically ordered silica structures from nano- to macro-scale at environmentally benign conditions and low energy costs (low temperature, low pressure, absence of caustic chemicals).

Abstract: The present invention relates to the use of recombinant silicatein-? or silicatein-? isolated from natural sources as well as to silicatein-?-fusion proteins as well as silicatein-?-related enzymes for the synthesis, the degradation and for modification of silicon dioxide (condensation products of silicic acid, silicates), silicones and other silicon(IV)- or metal(IV)-compounds, and their technical uses.

Abstract: The invention concerns the application of silicatein-silk fibroin fusion proteins in dentistry to synthesize silica-containing nanocomposite materials used as filling material.

Abstract: The present invention relates to a method for synthesis of amorphous silicon dioxide (silica, condensation products of silicic acid) and other polymeric metal (IV) compounds from non-organic silicon compounds or metal (IV) compounds as well as from aminosilanes and silazanes, whereby (I) a template (collagen or another molecule, interacting with orthosilicic acid or polymeric silicic acid and salts thereof or other metal (IV) compounds) and (2) a silicase/carbonic anhydrase or a silicatein or similar polypeptide are used for synthesis. Said invention also relates to the technical use thereof.

Abstract: The invention relates to a method for producing bioactive surfaces by enzymatic modification of molecules or molecular aggregates, in particular, collagen, on surfaces of glass, metals, metallic oxides, plastics, biopolymers or other materials with an amorphous silicon dioxide (silica) or silicones in the cell culture, by tissue engineering or in medical implants, whereby a polypeptide is used for enzymatic modification, which contains a silicatein ? or silicatein ? domain. The inventive method promotes the growth, activity and/or mineralization of cells/cell cultures.

Abstract: Silicatein is an enzyme of silicate-forming organisms used for the synthesis of their silicate scaffold. The present invention relates to the use of highly-expressed and highly active recombinant silicatein, silicatein isolated from natural sources after gene induction as well as silicatein-fusion proteins for the synthesis of amorphous silicon dioxide (silicic acids and silicates), siloxanes as well as modification of these compounds and their technical use.

Abstract: Silicatein is an enzyme of silicate-forming organisms used for the synthesis of their silicate scaffold. The present invention relates to the use of highly-expressed and highly active recombinant silicatein, silicatein isolated from natural sources after gene induction as well as silicatein-fusion proteins for the synthesis of amorphous silicon dioxide (silicic acids and silicates), siloxanes as well as modification of these compounds and their technical use.

Abstract: This invention relates to the establishment of a novel method of culturing sponge cells, coral cells and cells from other invertebrates in vitro. The cells cultured in vitro, which can be cultured as units similar to aggregates, are referred to as primmorphs. The method makes the following methods possible for the first time, using cells/aggregates/primmorphs from sponges, corals and other invertebrates: Methods (i) of preparing substances which modulate proliferation and DNA synthesis, (ii) of identifying/detecting environmentally harmful substances, (iii) of culturing bacteria and other micro-organisms, (iv) of preparing asexual reproductive bodies that can be used in aquaculture for growing corresponding organisms, (v) of preparing cell libraries, (vi) of optimising the nutritional requirements of the cells/aggregates/primmorphs, and (vii) of identifying substances which modulate telomerase activity in cells/aggregates/primmorphs.

Abstract: The invention relates to the use of flupirtine or its salts as drugs in the prophylaxis and therapy of diseases associated with an impairment of the haematopoetic cell system, for example lymphocytes. Especially important in this respect is the treatment of HIV infected patients/AIDS patients.

Abstract: The invention relates to the use of flupirtine or its salts as drugs in the prophylaxis and therapy of diseases associated with an impairment of the haematopoetic cell system, for example lymphocytes.Especially important in this respect is the treatment of HIV infected patients/AIDS patients.

Abstract: The antitumor and antiviral compound avarone, a process for its production, pharmaceutical compositions containing said compound, and a method of combating susceptible viruses and tumors therewith, are disclosed.

Abstract: The antitumor compound avarol, a process for its production, pharmaceutical compositions containing said compound, and a method of combating tumors therewith, are disclosed.

Abstract: The invention concerns the use of avarone and pharmaceutical compositions thereof for the control of AIDS and AIDS-Related Complex (ARC).

Abstract: The invention concerns the use of avarone and pharmaceutical compositions thereof for the control of adult T-cell leukemia/lymphoma.

Abstract: The antiviral compond avarol, a process for its production, pharmaceutical compositions containing said compound, and a method of combating viruses therewith, are disclosed.